Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma Clinical Trial

Official title:

Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00557830
• Other study ID #: AVJARCC0702
• Status: Terminated
• Phase: Phase 2
• First received: November 9, 2007
• Last updated: July 17, 2013
• Start date: January 2008
• Est. completion date: April 2011

Study information

• Verified date: July 2013
• Source: Accelerated Community Oncology Research Network
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC.

The secondary objectives are to evaluate the effects of the dose-escalation regimen on the quality of life (QoL) of patients with metastatic RCC and to characterize the safety and tolerability profile of a dose-escalation regimen of sorafenib in patients with metastatic RCC.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years old.

• Diagnosis of unresectable/metastatic renal cell carcinoma (RCC). Nonclear cell histology is permitted (except for medullary, collecting duct, or sarcomatoid >50% of specimen). Prior metastasectomy is permitted as long as there is measurable disease at time of consent.

• Karnofsky Performance Status of 50% or greater at study entry.

• Adequate bone marrow, liver and renal function as assessed by the following: o Hemoglobin = 9.0 g/dL. o ANC = 1500/mm3. o Platelet count = 100,000/mm3. o Total bilirubin = 1.5 ULN. o ALT and AST = 2.5 × ULN (= 5 × ULN for patients with liver involvement). o Creatinine = 1.5 × ULN.

• Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to the start of treatment.

• Women of childbearing potential and sexually active men must agree to use adequate barrier contraception prior to study entry, for the duration of study participation, and for at least three months after the last administration of sorafenib.

• INR < 1.5 or a PT/ PTT within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.

• Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures.

Exclusion Criteria:

• Prior systemic anticancer treatment for metastatic disease, including investigational therapy.

• Prior treatment with bevacizumab, sunitinib, or sorafenib even in the adjuvant setting.

• Prior cytokine therapy with interleukin (IL)-2 or interferon (IFN) for metastatic disease.

• Active malignancy other than RCC (except non-melanoma skin cancer) within 5 years of enrollment.

• Hemodialysis or peritoneal dialysis.

• Treatment with radiotherapy within 2 weeks of enrollment.

• Cardiac disease: Congestive heart failure Class II or higher per NYHA. Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.

• Uncontrolled CNS metastases. All patients must undergo a CT) scan/MRI of the brain to exclude brain metastasis. Patients with adequately treated CNS disease may be considered for participation as long as the first dose of sorafenib is 4 weeks after completion of CNS therapy.

• Uncontrolled hypertension defined as SBP > 150 mmHg or DBP > 90 mmHg, despite optimal medical management.

• Active clinically serious infection > Grade 2 per the CTCAE v3.

• Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.

• Pulmonary hemorrhage/bleeding event = Grade 2 per CTCAE v3.0 within 4 weeks of administration of the first dose of study drug.

• Any other hemorrhage/bleeding event = Grade 3 per CTCAE v3.0 within 4 weeks of administration of the first dose of study drug.

• Serious non-healing wound, ulcer, or bone fracture.

• Evidence or history of bleeding diathesis or coagulopathy.

• Major surgery, open biopsy or significant traumatic injury within 4 weeks of administration of the first study drug dose.

• Use of St. John's Wort, rifampin (rifampicin), phenytoin, Phenobarbital, carbamazepine, dexamethasone.

• Known or suspected allergy to sorafenib or any agent given in the course of this trial.

• Any condition that impairs patient's ability to swallow whole pills.

• Any malabsorption problem.

• Pregnancy or lactation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Renal Cell Carcinoma

Intervention

Drug:
• Sorafenib Escalated Dose
Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
• Sorafenib Standard Dose
Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.

Locations

Country	Name	City	State
United States	Northeast Georgia Cancer Care	Athens	Georgia
United States	Peachtree Hematology Oncology Consultants	Atlanta	Georgia
United States	Pacific Oncology, PC	Beaverton	Oregon
United States	Hematology Oncology Centers of the Northern Rockies	Billings	Montana
United States	Gaston Hematology and Oncology	Gastonia	North Carolina
United States	Clopton Clinic	Jonesboro	Arkansas
United States	Wilshire Oncology Medical Group, Inc.	La Verne	California
United States	The Lancaster Cancer Center, Ltd	Lancaster	Pennsylvania
United States	Central Georgia Cancer Care	Macon	Georgia
United States	Northwest Georgia Oncology Centers	Marietta	Georgia
United States	The West Clinic	Memphis	Tennessee
United States	Advanced Medical Specialties	Miami	Florida
United States	Mid-Illinois Hematology and Oncology Associates, Ltd.	Normal	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Accelerated Community Oncology Research Network	Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (CR + PR) Determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria.	Response was evaluated via changes from baseline in radiological tumor measurements performed every 8 weeks and at the end of treatment unless clinically indicated prior to that. Confirmatory scans were to be obtained no less than 4 weeks but no more than 6 weeks following initial documentation of objective response. Response was evaluated using RECIST criteria, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease; Progressive disease (PD) is at least a 20% increase in the sum of LD of target lesions or the appearance of one or more new lesions.	Overall response will be measured at baseline and every 8 weeks , unless clinically indicated prior to that, until the end of treatment.	No
Secondary	PFS Rate at 9, 13 and 17 Months	Due to the early study closure and the small sample size, the PFS rate at 9, 13, and 17 months were not evaluated.	PFS was to be measured at 9, 13, and 17 months.	No
Secondary	Overall Survival Rate	Due to the early study closure and the small sample size, overall survival rate was not evaluated.	Overall survival was measured from day 1 of treatment until the end of treatment and then every 4 months thereafter until death.	No
Secondary	Changes From Baseline in Symptom Burden	The Patient Care Monitor Version 2.0 (PCM) is an tablet computer based assessment system that measures patient reported outcomes (PROs) in medical patients with a particular emphasis on symptoms related to cancer and its treatment.; The PCM comprises 86 items which include 8 items answered only by females (e.g. menstrual cramping). Each item is presented so that the patient rates the degree to which the item has been a problem in the past week (0 not a problem to 10 as bad as possible).	The PCM was administered during screening, at each scheduled visit (approximately every 4 weeks), and at the end of treatment visit.	No